Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women between the ages of 18 and 65 who meet both RDC and DSM-IV criteria for bipolar I or bipolar II disorder will be recruited.~* All subjects will be interviewed using SADS interview (40) with added questions as to arrive at DSM-IV diagnoses as well.~* The patients will be treated with lamotrigine as their main mood stabilizer. Patients recruited for the study will show at least partial response to prophylactic treatment with respect to the mood symptoms.~* HAM-D (17 item) scores at study entry will be 15 or lower and Y MRS scores will be less than 15.~Exclusion Criteria:~* Patients not able to give informed consent~* Patients with active substance abuse or dependence or a history of such within the past two years~* Physical illness, mainly liver and kidney disorders and G-6-PD deficiency~* Subjects previously treated with methylene blue~* Pregnant or breast-feeding women~* Subjects who have had ECT within the past two years~* Patients with known brain injury or loss of consciousness of duration greater than ten minutes~* Subjects taking concurrent medications that are known to have cognitive effects (eg. beta blockers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).